{"filings":[{"id":93483,"accession_number":"0001437749-26-015590","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phio Pharma Q1 net loss $4.0M; PH-762 Phase 1b trial complete with favorable safety","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $17M at March 31, 2026; 2025 equity financings netted ~$23.7M, extending cash runway into H1 2027.","R&D expenses $2.8M (+215% YoY) driven by PH-762 clinical trial, CMC and toxicology costs.","G&A expenses $1.4M (+39% YoY) on higher employee costs, investor outreach and professional fees.","PH-762 dose-escalation study (22 patients) complete; final data being analyzed; FDA submission for next steps targeted Q2 2026.","ATM agreement with H.C. Wainwright in April 2026 allows up to $6.36M in common stock sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93482,"accession_number":"0001437749-26-011761","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2026-04-08T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Phio Pharmaceuticals enters ATM offering agreement with H.C. Wainwright for up to $6.36M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement allows sale of up to $6,360,000 of common stock via H.C. Wainwright as sales agent on an at-the-market basis.","H.C. Wainwright receives a 3.0% commission on gross proceeds; company reimburses up to $75,000 in legal fees.","No obligation to sell any shares; sales are made on Nasdaq Capital Market with T+1 settlement.","Company provides customary indemnification to the sales agent under the agreement.","The offering is registered under the company's existing S-3 shelf registration statement effective July 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105144,"accession_number":"0001437749-26-010164","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Phio signs cGMP manufacturing deal; PH-762 Phase 1b shows 85% pathological response","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered cGMP drug product manufacturing agreement with U.S. manufacturer for clinical and commercial supply of PH-762.","PH-762 Phase 1b trial: 22 patients completed, no dose-limiting toxicities or serious adverse events.","Pathological response rate across all cohorts ~65%; highest-dose cohort achieved 85% (6 of 7 patients).","FDA engagement for next-stage clinical development targeted for Q2 2026.","Cash and equivalents projected to sustain operations into H1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105143,"accession_number":"0001437749-26-007071","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phio Pharma reports 2025 net loss $8.7M; PH-762 Phase 1b dose escalation complete with favorable data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $8.7M ($1.45 EPS) for 2025 vs $7.2M ($9.08 EPS) in 2024; R&D expenses up 27%.","Cash at Dec 31, 2025: $21.0M vs $5.4M year ago; net proceeds from 2025 financings of $20.6M extend runway into H1 2027.","PH-762 Phase 1b dose escalation trial fully enrolled (22 patients); final cohort shows favorable safety, tolerability and pathology.","FDA submission seeking guidance on next steps for PH-762 targeted for Q2 2026; patent portfolio includes 54 issued patents.","Phio entered drug substance development agreement with US manufacturer and toxicology study agreement with US lab in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105142,"accession_number":"0001437749-26-004542","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Phio Pharmaceuticals amends CEO Bitterman's contract: severance to 12 months, bonus target to 50%","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Robert J. Bitterman's severance increased to 12 months base salary on termination without cause or for good reason.","Annual target bonus opportunity raised from 40% to 50% of base salary.","Amendment effective Feb 17, 2026; equity vesting acceleration unchanged.","No other changes to existing employment agreement terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105141,"accession_number":"0001437749-26-003575","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phio reports 85% pathological response in highest dose cohort of PH-762 Phase 1b trial; no serious adverse events","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["No serious adverse events or dose-limiting toxicities across all 22 patients in five dose cohorts.","85% pathological response (6/7 patients) in final cohort; 4 of 6 responders had complete tumor clearance.","Overall response rate of 65% for squamous cell carcinomas (13/20 pathologic responders, including 9 complete).","FDA submission for next-step guidance targeted for Q2 2026; cGMP manufacturing expected in H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105140,"accession_number":"0001437749-26-001500","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phio reports 70% ORR in cSCC from PH-762 trial; 10 of 14 responders had 100% clearance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["22 cutaneous carcinoma patients treated across 5 dose cohorts; no dose-limiting toxicities reported.","Among 20 cSCC patients, 14 responders; 10 complete (100% clearance), 2 major/near clear, 2 partial.","PH-762 well tolerated with 20-fold dose escalation; safety follow-up data expected in Q2 2026.","One Merkel cell carcinoma patient had partial response; no disease progression in any patient."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121397,"accession_number":"0001437749-25-038607","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phio Pharma gets FDA acceptance of PH-762 nonclinical study design; tox study Q1 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted nonclinical protocol study design for PH-762; toxicology study to begin Q1 2026.","Interim Phase 1b results: 6 complete responses among 16 evaluable cSCC patients; no dose-limiting toxicities.","Company advancing cGMP drug product delivery in 2026, partially funded by recent financing.","PH-762 well tolerated in all enrolled patients across five dose cohorts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121396,"accession_number":"0001437749-25-036329","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phio completes enrollment in Phase 1b trial of PH-762; positive pathologic responses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["18 patients treated across 5 dose cohorts; 16 with cSCC, 1 Merkel cell, 1 melanoma.","cSCC responses: 6 complete (100% clearance), 2 near complete (>90%), 2 partial (>50%).","Merkel cell patient had partial response (>50% clearance); no patients showed disease progression.","No dose-limiting toxicities or clinically relevant treatment-emergent adverse effects reported.","Highest dose cohort still enrolling; pathology results expected Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121395,"accession_number":"0001437749-25-034848","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phio Pharma Q3 net loss $2.4M; PH-762 trial 100% tumor clearance at max dose","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.4M for Q3 2025 vs $1.5M in Q3 2024; R&D expenses $1.2M, G&A $1.3M.","Phase 1b PH-762 trial: 100% tumor clearance (complete response) in one patient at max dose, >90% in second, >50% in third.","Cumulative pathologic results in 16 cSCC patients: 6 complete, 2 near complete, 2 partial responses; no dose-limiting toxicities.","November 2025 warrant inducement financing expected to raise ~$12.1M, extending cash runway into first half 2027.","Cash and equivalents $10.7M at Sep 30, 2025; estimated $21.3M as of release date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121394,"accession_number":"0001437749-25-033600","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Phio raises ~$13.4M via warrant exercise inducement; issues new warrants for 11.3M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered inducement agreements for exercise of 5,663,182 existing warrants at reduced prices; gross proceeds ~$13.4M.","First closings Nov 4 & 6 generated ~$12.6M; second expected by Nov 18 for remaining 350,000 warrants.","Issued new unregistered Series A warrants to purchase up to 11,326,364 shares at $2.05, 24-month term.","Proceeds to fund working capital and accelerate development of PH-762 for cutaneous carcinomas.","H.C. Wainwright acting as placement agent; fees include 7.5% cash fee and placement agent warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121393,"accession_number":"0001437749-25-032662","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phio Pharma: INTASYL PH-762 shows 100% tumor clearance in one cSCC patient; SMC clearance safe","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100% pathologic complete response in 1 of 3 cSCC patients at Day 36 in final dose cohort; >90% clearance in second, >50% in third.","Safety Monitoring Committee issued favorable review, no dose-limiting toxicities at max dose; PH-762 well tolerated across 5 cohorts.","Cumulative Phase 1b data: 6 complete, 2 near-complete, 2 partial responses among 16 cSCC patients; no clinical progression.","CEO notes PH-762 is promising non-surgical alternative for cutaneous carcinomas; trial continues to screen additional patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121392,"accession_number":"0001437749-25-032512","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-10-31T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Director Robert Ferrara resigns; David Deming appointed Lead Independent Director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Ferrara resigned effective Oct 31, 2025; no disagreement cited.","Board reduced from 6 to 5 members; no vacancies remain.","David Deming appointed Lead Independent Director; brings 30+ yrs investment banking (JP Morgan).","Deming joined Phio Board in Feb 2025; serves on Nominating Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138052,"accession_number":"0001683168-25-006985","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Phio stockholders approve 950,000-share increase to 2020 LTIP plan; adopt 3-year say-on-pay frequency","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six director nominees elected with 84-94% of votes cast; 1,828,465 broker non-votes.","Grant Thornton ratified as auditor for FY2025 with 2,330,465 votes for, 40,532 against.","2020 Plan amendment approved with 387,895 for, 152,069 against; shares available increased to 1,023,017.","Non-binding say-on-pay passed with 474,987 for (87% of votes cast).","Stockholders preferred 3-year say-on-pay frequency (276,177 votes); board adopted triennial vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138051,"accession_number":"0001683168-25-006641","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phio advances Phase 1b skin cancer trial to 5th cohort; presents at conference","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Patients are now being treated in the 5th cohort of the ongoing Phase 1b clinical trial for skin cancer (PH-762).","Phio Pharmaceuticals will present at H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025.","CEO Robert Bitterman will deliver an update on the trial and discuss strategy and next steps for the PH-762 program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138050,"accession_number":"0001683168-25-006171","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phio Pharma Q2 net loss $2.2M; advances PH-762 Phase 1b to 5th cohort","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.2M for Q2 2025 vs $1.8M in Q2 2024; cash $10.8M at June 30, 2025.","PH-762 Phase 1b trial: 15 patients treated, 5 complete responses in cSCC; enrolling final 5th cohort.","July 2025 warrant inducement raised ~$2.2M from exercise of existing warrants.","R&D expenses $1.1M in Q2 2025, up from $0.9M YoY due to enrollment costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138049,"accession_number":"0001683168-25-005523","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Phio Pharma receives ~$2.5M from warrant exercise, issues new warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$2.5M from exercise of 928,596 warrants at $2.00 and $2.485 per share.","Holders issued new unregistered Series J (5-yr term) and Series K (24-mo term) warrants for up to 1,857,192 shares at $2.485/share.","Holders paid additional $0.125 per new warrant ($232,149 aggregate) as part of inducement.","H.C. Wainwright receives 7.5% cash fee and placement agent warrants for 69,645 shares.","Net proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138048,"accession_number":"0001683168-25-005392","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phio reports complete response in cSCC and manufacturing agreement for PH-762","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered into comprehensive drug substance development agreement with U.S. manufacturer for PH-762.","Phase 1b fourth-cohort: one complete pathologic response (100% tumor clearance) in cSCC patient.","One partial response (>50% clearance) in stage 4 metastatic Merkel cell; two non-responses in cSCC.","No dose-limiting toxicities; PH-762 well tolerated across all cohorts; no clinical progression.","Enrolling 5th and expected final cohort in Phase 1b dose escalation study for cutaneous carcinomas."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138047,"accession_number":"0001683168-25-004948","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Phio sets 2025 annual meeting for Sept 11; new proposal deadlines","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting on Sept 11, 2025; record date July 18, 2025.","Rule 14a-8 stockholder proposals must be received by July 17, 2025.","Director nominations and other proposals not in proxy materials also due July 17, 2025.","Meeting date moved >30 days from 2024 anniversary, triggering revised deadlines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155460,"accession_number":"0001683168-25-004759","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phio Pharmaceuticals gets SMC nod to advance PH-762 skin cancer trial to fifth cohort","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Safety Monitoring Committee recommends dose escalation to fifth (final) cohort in Phase 1b trial of INTASYL PH-762.","No dose-limiting toxicities, serious adverse events, or clinically relevant treatment-emergent reactions in fourth cohort (5 patients).","To date, 15 patients treated; pathological complete response (100% clearance) seen in 4 of 9 cSCC patients from prior cohorts.","Enrollment in final cohort expected to complete in Q3 2025.","PH-762 is an intratumoral siRNA targeting cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155459,"accession_number":"0001683168-25-004421","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Phio Pharmaceuticals appoints Lisa Carson as CFO/PAO; Infarinato shifts to VP Strategic Development","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lisa Carson named VP Finance and Administration and designated principal financial and accounting officer, effective June 6, 2025.","Robert Infarinato ceased as PFO/PAO, appointed VP Strategic Development effective June 9 to focus on INTASYL portfolio business development.","Carson's compensation: $290k base salary, up to 30% annual bonus, $25k sign-on stipend; at-will employment.","Company announces strategic initiative to raise awareness of INTASYL siRNA portfolio (~30 compounds); positive interim Phase 1b results for PH-762 in skin cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155458,"accession_number":"0001683168-25-003715","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phio Pharma Q1 net loss $1.8M; PH-762 shows 4 complete responses in Phase 1b trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $13.3M at March 31 vs $5.4M Dec 31; raised $9.2M from offerings and $2.9M from warrant exercises.","Net loss $1.8M for Q1 2025 vs $2.2M in Q1 2024; R&D expenses down 23% to $0.886M.","Phase 1b PH-762: 4 of 9 cSCC patients had pathologic complete response; no dose-limiting toxicities.","4th cohort enrolling; company expects to complete enrollment in Q3 2025.","Sufficient capital to complete treatment phase of Phase 1b trial."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155457,"accession_number":"0001683168-25-003237","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phio Pharmaceuticals reports complete pathologic response in 2 of 3 patients in third cohort of INTASYL PH-762 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2 of 3 cSCC patients in Cohort 3 achieved 100% tumor clearance; third patient had <50% clearance.","Across 10 patients in Cohorts 1-3: 4 complete responses, 1 near complete (>90%), 1 partial (>50%).","No dose-limiting toxicities or clinically relevant adverse effects reported; PH-762 well tolerated.","Fourth cohort enrolling; Phio expects to complete trial enrollment in Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155456,"accession_number":"0001683168-25-002725","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Phio Pharmaceuticals dismisses BDO and engages Grant Thornton as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee dismissed BDO USA as independent auditor effective April 17, 2025.","Grant Thornton LLP appointed as new independent auditor for fiscal year ending Dec 31, 2025.","No disagreements or reportable events occurred during BDO's tenure through April 17, 2025.","BDO's reports for FY2024 and FY2023 included going-concern explanatory paragraphs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155455,"accession_number":"0001683168-25-002355","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phio gets SMC nod to advance PH-762 skin cancer trial to 4th dose cohort","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Safety Monitoring Committee recommended dose escalation to fourth cohort in Phase 1b trial (NCT06014086).","Third cohort (3 patients with cutaneous squamous cell carcinoma): no serious AEs, no dose-limiting toxicities.","Prior second cohort (4 patients): 2 complete responses (100% tumor clearance), 1 partial (90% clearance) at Day 36.","PH-762 is an intratumoral siRNA compound targeting cutaneous SCC, melanoma, and Merkel cell carcinoma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173955,"accession_number":"0001683168-25-002131","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phio Pharma FY24 net loss $7.2M; PH-762 Phase 1b with complete responses; $12.1M raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY24 was $7.2M ($9.08/share), down from $10.8M ($46.76/share) in FY23.","Cash at Dec 31, 2024 was $5.4M; subsequent financings added net $6.8M, total $12.1M raised.","PH-762 Phase 1b: 3rd cohort fully enrolled; in cohort 2, 2 complete responses and 1 partial response out of 4 patients.","R&D expenses decreased 42% to $3.7M due to cost rationalization and termination of AgonOx agreement.","Total proceeds of $9.2M from registered direct offerings and $2.9M from warrant exercises."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173954,"accession_number":"0001683168-25-001137","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Phio Pharmaceuticals appoints David H. Deming to Board of Directors, effective Feb 19, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded to six members; five of six are independent directors.","Deming will serve on the Nominating Committee immediately.","Over 30 years in investment banking; 27 years at JP Morgan leading Health Group in M&A.","Appointment effective February 19, 2025; term until 2025 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173953,"accession_number":"0001683168-25-000426","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-01-17T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Phio raises $1.83M via registered direct offering and warrant private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 610,000 shares at $3.00 each; issued warrants for 1,220,000 shares at $3.00 exercisable for 24 months.","Gross proceeds $1.83M; net ~$1.6M after fees; proceeds to be used for working capital and general corporate purposes.","H.C. Wainwright acted as placement agent; offering closed January 17, 2025.","Unregistered warrants issued under Section 4(a)(2); Company must register underlying shares within 30 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173952,"accession_number":"0001683168-25-000384","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Phio prices $2.5M registered direct offering of 833,335 shares at $3.00/sh; concurrent private placement of warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $2.5M; net ~$2.2M after fees and expenses.","Issued 833,335 common shares at $3.00/sh in registered direct offering.","Concurrent private placement of short-term warrants for up to 1,666,670 shares at $3.00, exercisable for 24 months.","Placement agent H.C. Wainwright receives 62,500 warrants at $3.75/sh plus cash fees.","Proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173951,"accession_number":"0001683168-25-000347","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Phio raises $3.19M in registered direct offering and warrant placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $3.19M; net ~$2.85M after fees and expenses.","Sold 1,063,670 shares at $3.00/share; issued warrants for up to 2,127,340 shares at $3.00, exercisable 24 months.","H.C. Wainwright acted as placement agent; received 7.5% cash fee plus 79,775 warrants at $3.75.","Net proceeds to be used for working capital and general corporate purposes.","Offering closed on January 14, 2025; priced at-the-market under Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173950,"accession_number":"0001683168-25-000274","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phio reports 2 complete responses in PH-762 Phase 1b second cohort for cutaneous squamous cell carcinoma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2 of 4 patients in 2nd cohort achieved 100% tumor clearance (complete response).","1 patient had 90% tumor clearance (partial response); 1 had stable disease.","No dose-limiting toxicities or clinically relevant adverse events reported.","INTASYL siRNA gene silencing therapy PH-762 is being evaluated in NCT 06014086."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190928,"accession_number":"0001683168-24-008984","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2024-12-26T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Phio raises ~$0.48M in registered direct offering of 240K shares at $2.00/share with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 240,000 shares of common stock at $2.00/share for gross proceeds of ~$0.48M; net ~$0.48M after expenses.","Issued warrants to purchase up to 240,000 additional shares at $2.00/share, exercisable immediately, expiring in 5 years.","H.C. Wainwright acted as placement agent; cash fees of 7.5% of gross proceeds plus management fee and warrants.","Proceeds to be used for working capital and general corporate purposes.","Closing occurred on Dec 24, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190927,"accession_number":"0001683168-24-008884","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Phio Pharma raises ~$1.15M in registered direct offering & private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$1.15M; net proceeds ~$900K after fees and expenses.","Sold 437,192 shares at $2.635/share in registered direct offering.","Concurrent private placement: warrants to purchase 437,192 shares at $2.51, 5-year term.","Proceeds to be used for working capital and general corporate purposes.","H.C. Wainwright acted as placement agent receiving 7.5% fee plus warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190926,"accession_number":"0001683168-24-008833","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phio Pharmaceuticals announces SMC recommendation to escalate to third dose cohort in PH-762 Phase 1b trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Safety Monitoring Committee reviewed safety data from second dose cohort and recommended escalation to next dose concentration.","First two patients in second cohort showed complete response (100% tumor clearance) and partial response (90% clearance) at Day 36.","No dose-limiting toxicities or serious adverse events reported in participants receiving intratumoral PH-762.","PH-762 is being studied for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma in Phase 1b trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190925,"accession_number":"0001683168-24-008118","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phio Pharma Q3 net loss $1.5M, cash $5.4M; PH-762 shows complete response in one patient","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $1.5M for Q3 2024 vs $2.8M in Q3 2023; R&D expenses fell 64% to $0.6M.","Cash at Sept 30, 2024 was $5.4M, down from $8.5M at Dec 31, 2023.","Phase 1b of PH-762: second cohort enrolled; one complete response (100% tumor clearance) and one partial response (90%) in cutaneous squamous cell carcinoma.","Warrant inducement exercise in July 2024 raised net proceeds of ~$2.6M.","Third cohort screening opens Dec 10, 2024; sixth clinical site added in San Diego."],"consensus_eps_estimate":null,"consensus_eps_actual":-8.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190924,"accession_number":"0001683168-24-007713","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phio reports Phase 1b data: complete & partial responses in cutaneous SCC patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Intratumoral PH-762 well tolerated with no related adverse events or dose-limiting toxicities across 5 patients.","Cohort 2: 1 complete response (100% tumor clearance) and 1 partial response (90% tumor clearance) in cutaneous squamous cell carcinoma.","Phase 1b trial ongoing; enrollment anticipated to complete in Q3 2025.","Data presented at SITC 2024 annual meeting in Houston, TX."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207413,"accession_number":"0001683168-24-005707","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phio Pharma Q2 net loss $1.8M, cash $4.7M; PH-762 trial progresses","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash at June 30, 2024: $4.7M vs $8.5M at Dec 31, 2023; net loss $1.8M vs $2.5M year ago.","Phase 1b trial for PH-762 received positive SMC safety recommendation; dose escalation and next cohort enrollment ongoing.","Nasdaq compliance regained for minimum $1.00 bid price after 9:1 reverse stock split effective July 5, 2024.","Appointed Robert M. Infarinato as VP and CFO effective August 1, 2024.","Entered exploratory collaboration with global skin care company for INTASYL cosmeceutical compounds."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207412,"accession_number":"0001683168-24-005194","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Phio Pharmaceuticals appoints Robert Infarinato as CFO effective August 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert M. Infarinato appointed VP & CFO effective August 1, 2024; will serve as principal financial and accounting officer.","Mr. Infarinato, 78, is an attorney and CPA with over 20 years of financial leadership in pharma and biotech.","Base salary $180,000; eligible for annual bonus up to 30% of base based on performance goals.","Caitlin Kontulis ceased as principal accounting officer on August 1 and will leave employment on August 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207411,"accession_number":"0001683168-24-005049","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2024-07-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Phio Pharmaceuticals regains Nasdaq minimum bid price compliance after reverse split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq notice on July 19, 2024, confirming compliance with Listing Rule 5550(a)(2).","Compliance achieved after 1-for-9 reverse stock split effective July 5, 2024.","Company continues trading on Nasdaq Capital Market; delisting risk removed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207410,"accession_number":"0001683168-24-004800","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Phio Pharmaceuticals raises $3.1M via warrant exercise at $5.45/share; issues new warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$3.1M from cash exercise of 545,286 existing warrants at reduced price of $5.45/share (original range $324-$9.72).","Holders pay additional $0.125 per new warrant for aggregate $136,321; total gross proceeds include this amount.","New Series C (583,098 shares, 5.5-yr term) and Series D (507,474 shares, 18-mo term) warrants issued, exercise price $5.45.","H.C. Wainwright acts as exclusive placement agent; receives 7.5% cash fee, $35k non-accountable expenses, and 40,896 warrants.","Net proceeds to be used for working capital and general corporate purposes; offering closed July 12, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207409,"accession_number":"0001683168-24-004683","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2024-07-05T23:59:59+00:00","items":["1.02","8.01","9.01"],"status":"ready","headline":"Phio terminates $621K share purchase agreement with Triton Funds after stock falls below floor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On July 3, 2024, Phio terminated the Purchase Agreement with Triton Funds LP, effective immediately.","The agreement allowed Triton to buy up to 95,833 shares at $6.48/share for gross proceeds up to $621,000.","No shares were ever sold under the agreement; termination followed a $5.23 close on July 3, below the $6.48 floor.","Phio's Board determined termination was advisable to pursue alternative financing.","Press release states the agreement would have allowed Triton to purchase up to 18.8% of common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207408,"accession_number":"0001683168-24-004619","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2024-07-02T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Phio Pharmaceuticals implements 1-for-9 reverse stock split effective July 5, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio set at 1-for-9; reduces outstanding shares from ~4.6M to ~0.5M.","Split effective 12:01 a.m. ET on July 5, 2024; trading symbol remains PHIO.","Adopted to meet Nasdaq minimum $1.00 bid price requirement for continued listing.","No fractional shares issued; cash payment in lieu for fractional holdings.","CUSIP changed to 71880W501; transfer agent Computershare managing exchange."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224826,"accession_number":"0001683168-24-004417","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Phio shareholders approve reverse stock split (1:2-1:9) and 500K share increase to LTIP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split proposal approved with 1,879,666 For, 313,572 Against; board to set exact ratio and effective date.","Amendment to 2020 Long Term Incentive Plan approved, increasing shares by 500,000 to total 725,500.","All five director nominees elected: Bitterman, Bradford, Ferrara, Freeman, Lockshin, each with >559K For votes.","Ratification of BDO USA as independent auditor for FY 2024 approved with 2,075,307 For votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224825,"accession_number":"0001683168-24-003849","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phio Pharma gets SMC OK to escalate PH-762 dose in Phase 1b; no dose-limiting toxicities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Safety Monitoring Committee recommended dose escalation to next concentration after initial cohort.","No dose-limiting toxicities or clinically relevant treatment-emergent adverse events observed.","PH-762 intratumoral injections were well tolerated in the first dose cohort.","Phase 1b trial (NCT06014086) targets cutaneous squamous cell carcinoma, melanoma, Merkel cell carcinoma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224824,"accession_number":"0001683168-24-003598","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Phio Pharmaceuticals enters purchase agreement with Triton Funds for up to $621k at $0.72 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to 862,500 shares at $0.72/share, representing ~18.8% of outstanding shares.","Gross proceeds up to $621,000; agreement expires Nov 17, 2024 or upon full sale.","Triton has covenanted not to engage in any short selling of PHIO common stock.","Offered under existing shelf registration; prospectus supplement to be filed.","Company may request purchases in one or more transactions based on market conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224823,"accession_number":"0001683168-24-003178","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phio Pharmaceuticals Q1 2024 net loss narrows to $2.2M; cash at $6.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash of $6.5M at March 31, 2024, down from $8.5M at Dec 31, 2023.","Net loss of $2.2M for Q1 2024 vs $3.6M in prior-year quarter; R&D expenses fell 46% to $1.1M.","Phase 1b trial of PH-762 in skin cancers has enrolled 3 patients at 4 U.S. sites.","USPTO granted patents for INTASYL compounds RXI-185 and RXI-231 targeting age-related skin disorders."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224822,"accession_number":"0001683168-24-002050","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phio Pharmaceuticals reports 2023 net loss of $10.8M; cash at $8.5M with PH-762 trial progress","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $10.8M ($5.20/share) vs $11.5M ($10.10/share) in 2022; R&D expenses down 10% to $6.3M.","Cash at Dec 31, 2023: $8.5M, down from $11.8M at end of 2022.","PH-762 Phase 1B: two patients completed treatment with no adverse events; four clinical sites under contract.","Headcount reduced 36% and Marlborough lease not renewed; moved to 321 sq ft lab in Worcester.","AgonOx study delayed; facility renovation expected to reopen May 2024; third patient infused in Nov 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244098,"accession_number":"0001683168-24-000489","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2024-01-26T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Phio Pharmaceuticals receives Nasdaq delisting notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency notice on Jan 24, 2024; stock failed to maintain $1.00 minimum bid for 30 consecutive business days.","Initial compliance period ends July 22, 2024; can regain by closing at $1.00 or more for 10 consecutive business days.","No immediate effect on listing or trading; company evaluating options to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261511,"accession_number":"0001683168-23-008732","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2023-12-08T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Phio raises $2.8M via warrant exercise at $1.33, issues new warrants at $1.08","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Existing warrant holders exercise 2,130,252 shares at reduced price of $1.33/share; gross proceeds ~$2.8M.","Phio issues new unregistered Series A and Series B warrants to purchase up to 4,260,504 shares at $1.08/share.","Series A warrants have a 5.5-year term; Series B warrants have an 18-month term.","H.C. Wainwright serves as exclusive placement agent; receives 7.5% cash fee and 159,769 placement agent warrants.","Net proceeds intended for working capital and general corporate purposes; offering expected to close Dec 8, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261510,"accession_number":"0001683168-23-007815","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Phio Pharma Q3 net loss narrows to $2.8M; first patient dosed in PH-762 Phase 1b trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss $2.8M ($1.14/sh) vs $3.6M ($3.14/sh) in Q3 2022; cash at Sep 30 $8.4M down from $11.8M at Dec 31 2022.","R&D expenses fell 28% YoY to $1.8M; G&A fell 9% to $1.0M.","First patient dosed in U.S. Phase 1b trial of intratumoral PH-762 (anti-PD-1) for skin carcinomas (NCT06014086).","Trial expected to enroll up to 30 patients across 4-6 U.S. sites; neoadjuvant monotherapy with dose escalation.","Company presented preclinical data on PH-894 (BRD4) and CTLA-4-targeting INTASYL at recent conferences."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12995056.86690909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-11-09T23:59:59+00:00|261510"}